Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Dermatologie (Heidelb) ; 74(1): 55-64, 2023 Jan.
Artículo en Alemán | MEDLINE | ID: mdl-36595033

RESUMEN

Nailfold capillaroscopy is a rapid and easily applicable differential diagnostic technique that allows direct visualization of the microcirculation. Abnormal findings in nailfold capillaroscopy are closely associated with connective tissue diseases, such as systemic sclerosis. The clinical manifestation of impaired microcirculation is Raynaud's phenomenon, which is a classical symptom of connective tissue diseases. Nailfold capillaroscopy is increasingly used in various fields of medicine, therefore it is important to define methods for the acquisition and analysis of the results of nailfold capillary and to have a uniform definition of abnormal capillaries. This article discusses image acquisition and analysis, various capillaroscopic techniques, normal and abnormal capillaroscopic features and their significance, scoring systems and reliability of image acquisition and interpretation.


Asunto(s)
Enfermedades del Tejido Conjuntivo , Esclerodermia Sistémica , Humanos , Uñas/diagnóstico por imagen , Angioscopía Microscópica/métodos , Reproducibilidad de los Resultados , Enfermedades del Tejido Conjuntivo/diagnóstico , Esclerodermia Sistémica/diagnóstico
2.
Z Rheumatol ; 81(7): 596-604, 2022 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-35532799

RESUMEN

INTRODUCTION: The concept of complex multimodal rheumatologic treatment (CMRT) has been established for several years in German rheumatologic departments and aims at a multifaceted therapeutic approach to patients with rheumatic diseases. Objective of this study was to examine the therapeutic effect of CMRT in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in an acute rheumatology center. METHODS: The treatment success of CMRT was evaluated by epidemiologic data, patient questionnaires on visual analog scales (VAS) regarding morning stiffness, pain and disease activity (DA), as well as clinical scores (Disease Activity Score 28 [DAS28], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Bath Ankylosing Spondylitis Functional Index [BASFI]), laboratory inflammation markers (CRP, erythrocyte sedimentation rate) and medication in three visits: visit 1 = begin of CMRT; visit 2 = end of CMRT; visit 3 = 3 months after CMRT. RESULTS: In this study 162 patients from the Rheumatology Center, Rhineland-Palatinate, Germany (96 (59.3%) RA, 30 (18.8%) AS, 36 (22.2%) PsA) were recruited. Statistical examinations revealed a significant improvement of VAS(DA) (visit 2 versus visit 1: RA: p = 0.02, AS: p < 0.001, PsA: p < 0.001), morning stiffness (RA: p < 0.001, AS: p = 0.03, PsA: p < 0.001) and patient reported pain (all; p < 0.001) in the context of CMRT. In the RA and AS subgroups improvements of DAS28 and BASDAI could also be observed (visit 2 versus visit 1: both; p < 0.001). Moreover, significant improvement of patient reported outcomes could be observed 3 months after CMRT regarding VAS(DA) (RA: p = 0.02 und AS: p = 0.03, morning stiffness (PsA: p = 0.02) and patient reported pain (RA: p = 0.01)). Interestingly, subgroup analyses showed that the therapeutic benefit was independent of the concomitant pharmacotherapy. CONCLUSION: The results of this study suggest a therapeutic benefit for patients being treated by CMRT and highlight the high value of this therapeutic concept in patients with systemic-inflammatory rheumatic diseases.


Asunto(s)
Artritis Psoriásica , Artritis Reumatoide , Reumatología , Espondilitis Anquilosante , Artritis Psoriásica/diagnóstico , Artritis Psoriásica/tratamiento farmacológico , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/tratamiento farmacológico , Humanos , Dolor , Índice de Severidad de la Enfermedad , Espondilitis Anquilosante/tratamiento farmacológico
3.
Z Rheumatol ; 81(4): 313-322, 2022 May.
Artículo en Alemán | MEDLINE | ID: mdl-35445832

RESUMEN

Nailfold capillaroscopy is a rapid and easily applicable differential diagnostic technique that allows direct visualization of the microcirculation. Abnormal findings in nailfold capillaroscopy are closely associated with connective tissue diseases, such as systemic sclerosis. The clinical manifestation of impaired microcirculation is Raynaud's phenomenon, which is a classical symptom of connective tissue diseases. Nailfold capillaroscopy is increasingly used in various fields of medicine, therefore it is important to define methods for the acquisition and analysis of the results of nailfold capillary and to have a uniform definition of abnormal capillaries. This article discusses image acquisition and analysis, various capillaroscopic techniques, normal and abnormal capillaroscopic features and their significance, scoring systems and reliability of image acquisition and interpretation.


Asunto(s)
Enfermedades del Tejido Conjuntivo , Enfermedad de Raynaud , Esclerodermia Sistémica , Capilares/diagnóstico por imagen , Enfermedades del Tejido Conjuntivo/diagnóstico por imagen , Humanos , Angioscopía Microscópica/métodos , Uñas/irrigación sanguínea , Uñas/diagnóstico por imagen , Enfermedad de Raynaud/diagnóstico , Reproducibilidad de los Resultados , Esclerodermia Sistémica/diagnóstico
4.
Rheumatology (Oxford) ; 60(SI): SI51-SI58, 2021 10 09.
Artículo en Inglés | MEDLINE | ID: mdl-33704418

RESUMEN

OBJECTIVES: To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany. METHODS: From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated. RESULTS: The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients (<60 years) reported just as often as older patients to discontinue their therapy. CONCLUSION: The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician-patient relationship in times of a crisis.


Asunto(s)
COVID-19/prevención & control , Prescripciones de Medicamentos/estadística & datos numéricos , Cumplimiento de la Medicación/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Cuarentena/estadística & datos numéricos , Enfermedades Reumáticas/tratamiento farmacológico , Adulto , Antirreumáticos/uso terapéutico , Estudios Transversales , Femenino , Alemania , Humanos , Factores Inmunológicos/uso terapéutico , Masculino , Persona de Mediana Edad , SARS-CoV-2
5.
Z Rheumatol ; 79(4): 379-384, 2020 May.
Artículo en Alemán | MEDLINE | ID: mdl-32303821

RESUMEN

The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (www.dgrh.de), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society.


Asunto(s)
Infecciones por Coronavirus , Huésped Inmunocomprometido , Cumplimiento de la Medicación , Pandemias , Neumonía Viral , Enfermedades Reumáticas/inmunología , Antirreumáticos/efectos adversos , Antirreumáticos/uso terapéutico , Betacoronavirus , COVID-19 , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/inmunología , Estudios Transversales , Humanos , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Neumonía Viral/epidemiología , Neumonía Viral/inmunología , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/tratamiento farmacológico , SARS-CoV-2
6.
Z Rheumatol ; 79(7): 718-724, 2020 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-31848701

RESUMEN

BACKGROUND: Scleroderma or systemic sclerosis (SSc) is a rare autoimmune rheumatic connective tissue disease. The clinical picture is manifold and symptoms can vary greatly between different patients. All manifestations are possible ranging from isolated skin involvement up to systemic disease with multiple organ manifestations. Due to this inhomogeneous clinical picture, it often takes years until the correct diagnosis is made and adequate treatment is started. METHODS: Patients with the main or secondary diagnosis of systemic sclerosis (M34) between 2002 and 2017 were retrospectively recorded from the patient databases of the ACURA clinic for acute rheumatology in Bad Kreuznach and the data were evaluated. Of special interest were pulmonary parameters over the course of time. Furthermore, standardized questionnaires were distributed to general practitioners in Rhineland-Palatinate via the Association of Statutory Health Insurance Physicians as well as to patients admitted to the hospital (2016-2017). RESULTS: A total of 135 patients could be evaluated. For women the median age of onset was 52 years (interquartile range, IQR 44-64 years) and for men the median age of onset was 49 years (IQR 38-54 years). Lung involvement was detected in 54% of the cases. Including the individual time to diagnosis, there was a significant worsening of the diffusing capacity for carbon monoxide (73% vs. 56%, p = 0.046) between earlier (<4 months) and later (4-18 months) diagnoses, which also persisted in the follow-up (74% vs. 53%) despite adequate treatment. CONCLUSION: A rapid diagnosis within 3 months of the onset of Raynaud's phenomenon seems to play a key role in the preservation of lung function.


Asunto(s)
Enfermedades del Tejido Conjuntivo , Enfermedad de Raynaud , Esclerodermia Sistémica , Adulto , Comorbilidad , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Raynaud/diagnóstico , Enfermedad de Raynaud/epidemiología , Estudios Retrospectivos , Esclerodermia Sistémica/diagnóstico , Esclerodermia Sistémica/epidemiología
7.
Z Rheumatol ; 78(7): 660-669, 2019 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-31165251

RESUMEN

BACKGROUND/OBJECTIVE: The majority of patients in Germany miss out on the necessity of early diagnosis and initiation of therapy for rheumatoid arthritis (RA) caused by considerable structural deficits in the health care system. The challenge is to reconcile the individual demand for the best possible therapy result with a sustainable expenditure of resources. METHODS: The cross-sectoral regional care network ADAPTHERA aims to improve early RA diagnosis and treatment in Rhineland-Palatinate. The retrospective triage analyses of suspected early onset RA patients was performed by tracing the selection process of all available enquiries (n = 1045). For analysis of the clinical course of the disease, a subset comprising 143 patients with a minimum observation time of 12 months (5 consecutive visits) was available. Clinical and laboratory parameters were collected quarter yearly, self-administered questionnaires were filled out and the treatment was adapted if necessary. RESULTS: A total of 454 patients were included. The mean waiting time was 23.9 (SD = 18) days. The mean observation period in the subcohort was 29.2 (SD = 12.7) months, with about 50% of the patients presenting within 3 months. Almost 75% of the patients were in remission after 2 years. A sustained remission could be described for 74.8% (6 months) and 53.5% (12 months), respectively. Especially patients with rapid remission induction benefited in terms of longer remissions (p = 0.03). A very early stage of the disease (VERA) was associated with a rarely necessary biologic therapy (p = 0.022). DISCUSSION: The approach of a supply network is not a panacea, but it might improve healthcare for patients with early onset RA. In order to minimize resource utilization, a pinpoint referral and accurate triage of potential cases are crucial.


Asunto(s)
Antirreumáticos , Artritis Reumatoide , Antirreumáticos/uso terapéutico , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/tratamiento farmacológico , Prestación Integrada de Atención de Salud , Alemania , Humanos , Inducción de Remisión , Estudios Retrospectivos , Resultado del Tratamiento
8.
Z Rheumatol ; 78(7): 670-676, 2019 Sep.
Artículo en Alemán | MEDLINE | ID: mdl-31016369

RESUMEN

BACKGROUND AND OBJECTIVE: For patients with established rheumatoid arthritis and also early arthritis an increased prevalence of depression has been described. For a better understanding of depression in early arthritis patients, depression prevalences of a German early arthritis cohort were examined, with a focus on disease activity, anti-CCP status, disease duration and functional capacity over a period of 2 years. MATERIAL AND METHODS: The evaluation was based on the early arthritis cohort ADAPTHERA from Rhineland-Palatinate. The inclusion criterion was a symptom duration before diagnosis of a maximum of 1 year. Data from the disease activity score 28 (DAS28), the Health Assessment Questionnaire (HAQ, functional status), the WHO-5 Well-Being Index (WHO-5, well-being and depressive symptoms) and the Patient Health Questionnaire-9 (PHQ-9, depressive symptoms) were collected. RESULTS: At the beginning, 43.5% of patients had depressive symptoms (WHO-5 > 28). After the 2 year follow-up the percentage of patients with depressive symptoms had reduced to 20.8%. Correlations with disease activity according to DAS28 and the function of HAQ could be confirmed. There was no correlation between depressive symptoms and anti-CCP status (p = 0.431) or duration from symptom onset to diagnosis (p = 0.671). CONCLUSION: Screening of early arthritis patients for the presence of depressive symptoms is of essential importance. Patients seem to be at high risk of developing depressive symptoms especially at the beginning of the disease and when showing high disability and poor results on disease activity score (DAS28 and visual analog scale).


Asunto(s)
Artritis Reumatoide , Depresión , Artritis Reumatoide/psicología , Estudios de Cohortes , Depresión/epidemiología , Depresión/etiología , Evaluación de la Discapacidad , Humanos , Índice de Severidad de la Enfermedad
9.
Reumatismo ; 70(4): 257-258, 2018 12 20.
Artículo en Inglés | MEDLINE | ID: mdl-30570244

RESUMEN

A 57-year-old woman with a diagnosis of antisynthetase syndrome (ASSD) underwent a nailfold videocapillaroscopy (NVC) showing a scleroderma pattern. Alterations in capillary morphology have been reported in adults with inflammatory myositis (IM) but only recently have the differences in NVC findings between these two diseases been established. ASSD is currently classified as a subset of IM, for which reason only a few studies in literature evaluate its specific hallmarks, showing nonspecific features of NVC in patients with polymyositis and dermatomyositis (DM) and antisynthetase antibodies. To our knowledge, this is the first description of ASSD capillaroscopy features, and the first report of NVC in ASSD with evidence of scleroderma pattern. Further studies are needed to define clearly frequency, typical features, and possible correlation with clinical and serological data of NVC changes in ASSD, differences between microangiopathy in ASSD and systemic sclerosis or DM.


Asunto(s)
Angioscopía Microscópica , Miositis/diagnóstico por imagen , Femenino , Humanos , Persona de Mediana Edad
10.
Lupus ; 27(2): 243-256, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28659046

RESUMEN

B-cell activating factor of the tumour necrosis factor family (BAFF) is a cytokine, mainly produced by hematopoietic cells (e.g. monocytes/macrophages, dendritic cells), indispensable for B-cell maturation. The BLISS studies have demonstrated that blocking BAFF by the human monoclonal antibody belimumab is a valuable therapeutic approach in patients with clinically and serologically active systemic lupus erythematosus (SLE). However, the defined sources of BAFF, which contributes to SLE, are still unclear. Recent findings show that BAFF expression is not restricted to myeloid cells. Since lupus nephritis is the main cause of morbidity and mortality for SLE patients, the aim of this study was to investigate whether renal tubular epithelial cells (TEC) are an important source of BAFF and thus may contribute to the pathogenesis and progression of SLE. We found BAFF expression both in cultured murine and human TEC. These results could be verified with in situ data from the kidney. Moreover, BAFF expression in the kidneys of lupus-prone MRL- Faslpr mice correlated with disease activity, and BAFF expression on TEC in biopsies of patients with diffuse proliferative lupus nephritis showed a correlation with the histopathological activity index. In vitro functional assays revealed an autocrine loop of BAFF with its binding receptors on TEC, resulting in a strong induction of colony stimulating factor-1. Finally, we identified divergent effects of BAFF on TEC depending on the surrounding milieu ('inflammatory versus non-inflammatory'). Taken together, our findings indicate that renal-derived BAFF may play an important role in the pathophysiology of the systemic autoimmune disease SLE.


Asunto(s)
Factor Activador de Células B/efectos de los fármacos , Células Epiteliales/metabolismo , Riñón/citología , Lupus Eritematoso Sistémico/tratamiento farmacológico , Nefritis Lúpica/patología , Animales , Anticuerpos Monoclonales Humanizados/administración & dosificación , Anticuerpos Monoclonales Humanizados/farmacología , Factor Activador de Células B/metabolismo , Linfocitos B/inmunología , Citocinas/metabolismo , Femenino , Humanos , Inmunosupresores/farmacología , Riñón/patología , Enfermedades Renales/patología , Lupus Eritematoso Sistémico/fisiopatología , Nefritis Lúpica/mortalidad , Masculino , Ratones , Receptores de Factor Estimulante de Colonias de Granulocitos y Macrófagos , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Factor de Necrosis Tumoral alfa/metabolismo
11.
Z Rheumatol ; 75(10): 999-1005, 2016 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-27535273

RESUMEN

The aim of the rheumatology network ADAPTHERA ("risk-adapted rheumatology therapy") is to achieve a comprehensive improvement in rheumatology care by coordinating treatment in a regional, trans-sectoral network. Accompanying biomedical research projects, training concepts, and the construction of a rheumatology register (gathering data and biomaterials) should furthermore ensure the stable and sustainable optimisation of care. In the pilot phase (2012-2015) the focus of the ADAPTHERA network, required as a "regional key project" within the framework of the Initiative on Health Economy of Rheinland-Palatinate (RL-P), Germany, was placed on the optimisation of the early diagnosis of rheumatoid arthritis, where it is well-known that there is a significant care deficit.Through the intensive, stable, and coordinated cooperation of all health care partners in the field of rheumatology (registered general practitioners and orthopaedic specialists, registered core rheumatologists as well as the Association of Rheumatology of RL-P) a unique regional, comprehensive offer with verifiable care optimisation has been established in RL-P. The network is supported by outstanding collaboration with the Association of Statutory Health Insurance Physicians and the self-help organisation Rheumatology League.The aims that were established at the start of the project will be achieved by the end of the pilot phase:- significant improvement in the early diagnosis of rheumatoid arthritis (an average of 23.7 days until diagnosis by rheumatologists)- access covering all health insurance (regardless of the particular scheme the patients belong to)- comprehensive (verifiable participation of general practitioners from all over RL-P)- data and biomaterials collection, established as a basis for biomarker research, and a rheumatology register for RL-P.


Asunto(s)
Prestación Integrada de Atención de Salud/organización & administración , Programas Nacionales de Salud/organización & administración , Programas Médicos Regionales/organización & administración , Enfermedades Reumáticas/diagnóstico , Enfermedades Reumáticas/terapia , Reumatología/organización & administración , Atención a la Salud/organización & administración , Humanos , Modelos Organizacionales , Sistema de Registros
12.
Z Rheumatol ; 72(9): 916-20, 2013 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-24129423

RESUMEN

The clinical picture of enlarged submandibular gland and/or enlarged lacrimal gland often leads to difficulties in differential diagnostics. From the perspective of rheumatology Sjögren's syndrome should be excluded especially in patients who complained of xerophthalmia and xerostomia for longer than 3 months. In this article the authors report the case of a patient who presented to clarify swelling of the submandibular gland and xerostomia. In close cooperation with rheumatologists, otolaryngologists and pathologists the diagnosis of IgG4-associated sialoadenitis (IgG4-associated Mikulicz's disease) could be reached.


Asunto(s)
Inmunoglobulina G/inmunología , Enfermedad de Mikulicz/diagnóstico , Enfermedad de Mikulicz/inmunología , Prednisolona/administración & dosificación , Síndrome de Sjögren/diagnóstico , Síndrome de Sjögren/inmunología , Xerostomía/diagnóstico , Antiinflamatorios/administración & dosificación , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Mikulicz/tratamiento farmacológico , Síndrome de Sjögren/tratamiento farmacológico , Resultado del Tratamiento , Xerostomía/inmunología , Xerostomía/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...